Enlarging the "Audacious Goal": Elimination of the world's high prevalence neglected tropical diseases

Vaccine

Volumn 29, Issue SUPPL. 4, 2011, Pages

  Hotez, Peter ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Ascariasis; Blinding trachoma; Disease; Disease eradication; Elimination; Hookworm infection; Kinetoplastid infections; Leprosy; Lymphatic filariasis (LF); Neglected tropical diseases; Onchocerciasis; Schistosomiasis; Trichuriasis

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B LIPID COMPLEX; ANTHELMINTIC AGENT; ANTISCHISTOSOMAL AGENT; ANTITRYPANOSOMAL AGENT; AZITHROMYCIN; DIETHYLCARBAMAZINE; DOXYCYCLINE; IVERMECTIN; MEBENDAZOLE; MILTEFOSINE; PAROMOMYCIN; TETRACYCLINE; VACCINE;

AFRICAN TRYPANOSOMIASIS; ARTICLE; ASCARIASIS; BLINDING TRACHOMA; BRAZIL; CHAGAS DISEASE; CHINA; DEVELOPING COUNTRY; DISEASE CONTROL; DISEASE SURVEILLANCE; DRACUNCULIASIS; DRUG MEGADOSE; HEALTH PROGRAM; HOOKWORM INFECTION; HUMAN; INDIA; LEISHMANIASIS; LEPROSY; LYMPHATIC FILARIASIS; MASS DRUG ADMINISTRATION; MEDICAL SOCIETY; MEXICO; MIDDLE EAST; NEGLECTED TROPICAL DISEASE; NIGERIA; NONHUMAN; ONCHOCERCIASIS; PREVALENCE; PRIORITY JOURNAL; SCHISTOSOMIASIS; SINGLE DRUG DOSE; TRACHOMA; TRICHURIASIS; TROPICAL DISEASE;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DISEASE ERADICATION; HUMANS; NEGLECTED DISEASES; PARASITIC DISEASES; PREVALENCE; TROPICAL CLIMATE; WORLD HEALTH;

EID: 84857809426     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.024     Document Type: Article

References (49)

1. accessed November 28, 2010. http://www.gatesfoundation.org/press-releases/Pages/course-for-malaria-eradication-07017-aspx.
2. Hotez P.J. The National Institutes of Health roadmap and the developing world. J Investig Med 2004, 52:246-247.
3. Hotez P.J., Fenwick A., Savioli L., Molyneux D.H. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009, 373:1570-1575.
4. Hotez P.J. Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clin Pharmacol Therap 2009, 85:659-664.
5. Hotez P.J., Pecoul B. Manifesto for the control and elimination of the neglected tropical diseases. PLoS Negl Trop Dis 2010, 4:e718.
6. World Health Organization. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases 2010; 172 p., accessed May 9, 2011. http://www.who.int/neglected_diseases/2010report/en/.
7. World Health Organization Soil-transmitted helminthiasis. Weekly Epidemiol Rec 2008, 83:237-252.
8. Keiser J., Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008, 299:1937-1948.
9. Thein-Hlaing, Than-Saw, Htay-Htay-Aye, Myint-Lwin, Thein-Maung-Myint Epidemiology and transmission dynamics of Ascaris lumbricoides in Okpo village, rural Burma. Trans R Soc Trop Med Hyg 1984, 78:497-504.
10. Croll N.A., Anderson R.M., Gyorkos T.W., Ghadirian E. The population biology and control of Ascaris lumbricoides in a rural community in Iran. Trans R Soc Trop Med Hyg 1982, 76:187-197.
11. Hotez P.J., Bethony J.M., Diemert D.J., Pearson M., Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010, 8:814-826.
12. Reddy M., Gill S.S., Kalkar S.R., Wu W., Anderson P.J., Rochon P.A. Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA 2007, 298:1911-1924.
13. Dixon H., Johnston C.E., Else K.J. Antigen selection for future anti-Trichuris vaccines: a comparison of cytokine and antibody responses to larval and adult antigen in a primary infection. Parasite Immunol 2008, 30:454-461.
14. Spiegel J.M., Dharamsi S., Wasan K.M., Yassi A., Singer B., Hotez P.J., et al. Which new approaches to tackling neglected tropical diseases show promise?. PLoS Med 2010, 7:e1000255.
15. King C.H. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010, 113:95-104.
16. Utzinger J, N'goran EK, Caffrey CR, Keiser J. From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop, 2010. [Epub ahead of print].
17. Gray D.J., McManus D.P., Li Y., Williams G.M., Bergquist R., Ross A.G. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis 2010, 10:733-736.
18. Hotez P.J., Engels D., Fenwick A., Savioli L. Africa is desperate for praziquantel. Lancet 2010, 376:496-498.
19. Hotez P.J., Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl Trop Dis 2009, 3:e485.
20. Hotez P.J., Bethony J.M., Oliveira S.C., Brindley P.J., Loukas A. Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis. Expert Rev Vaccines 2008, 7:745-752.
21. Taylor M., Hoerauf A., Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010, 376:1175-1185.
22. World Health Organization. Global Programme to Eliminate Lymphatic Filariasis. Progress Report 2000-2009 and Strategic Plan 2010-2020, 2010; 80 p.
23. Bockarie M.J., Deb R.M. Elimination of lymphatic filariasis: do we have the drugs to complete the job?. Curr Opin Infect Dis 2010, 23:617-620.
24. Diawara L., Traoré M.O., Badji A., Bissan Y., Doumbia K., Goita S.F., et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009, 3:e497.
25. Lustigman S., James E.R., Tawe W., Abraham D. Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends Parasitol 2002, 18:138-141.
26. Massad E. The elimination of Chagas' disease from Brazil. Epidemiol Infect 2008, 136:1153-1164.
27. Reithinger R., Tarleton R., Urbina J.A., Kitron U., Gurtler R.E. Eliminating Chagas disease. BMJ 2009, 338:1044-1046.
28. Carzola S.I., Frank F.M., Malchiodi E.L. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 2009, 8:921-935.
29. Alvar J., Aparicio P., Aseffa A., Den Boer M., Cañavate C., Dedet J.P., et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008, 21:334-359.
30. Mondal D., Singh S.P., Kumar N., Joshi A., Sundar S., Das P., et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 2009, 3:e355.
31. World Health Organization. Research to support the elimination of visceral leishmaniasis. TDR Business Line 10. Annual Report 2009, 22 p.
32. Bertholet S., Goto Y., Carter L., Bhatia A., Howard R.F., Carter D., et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009, 27:7036-7045.
33. Llanos-Cuentas A., Calderón W., Cruz M., Ashman J.A., Alves F.P., Coler R.N., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combinnation with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 2010, [Epub ahead of print].
34. Nascimento E., Fernandes D.F., Vieira E.P., Campos-Neto A., Ashman J.A., Alves F.P., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010, 28:5581-5587.
35. Sakai S., Takashima Y., Matsumoto Y., Reed S.G., Hayashi Y., Matsumoto Y., et al. Intranasal immunization with Leish-111f induces IFN-gmama production and protects mice from Leishmania major infection. Vaccine 2010, 28:2207-2213.
36. Trigo J., Abbehusen M., Netto E.M., Nakatani M., Pedral-Sampaio G., de Jesus R.S., et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 2010, 28:3333-3340.
37. Vélez I.D., Gilchrist K., Martínez S., Ramírez-Pineda J.R., Ashman J.A., Alves F.P., et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009, 26:329-337.
38. Oliveira F, Lawyer PG, Kamhawi S, Valenzuela JG. Immunity to distinct sand fly salivary protein primes the anti-lieshmania immune response towards protection or exacerbation of disease. PLoS Negl Trop Dis 2008; 2: e226.
39. World Health Organization Meeting of the international task force for disease eradication-October 2010. Weekly Epidemiol Rec 2011, 86:53-60.
40. Porco T.C., Gebre T., Ayele B., House J., Keenan J., Zhou Z., et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009, 302:962-968.
41. World Health Organization Global leprosy situation 2010. Weekly Epidemiol Rec 2010, 85:337-348.
42. Richardus J.H., Habbema J.D. The impact of leprosy control on the transmission of M. leprae: is elimination being attained?. Lepr Rev 2007, 78:330-337.
43. accessed December 6, 2010. http://www.who.int/lep/en/index.html.
44. Saunderson P.R. Leprosy elimination: not as straightforward as it seemed. Publ Health Rep 2008, 123:213-216.
45. Hotez P.J., Ferris M.T. The antipoverty vaccines. Vaccine 2006, 24:5787-5799.
46. Hotez P. A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Affairs 2011, 30:1080-1087.
47. Pullan R., Brooker S. The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases. Parasitol 2008, 135:783-794.
48. Hotez P.J. New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's global health initiative (GHI). PLoS Negl Trop Dis 2011, 5:e1133.
49. Hotez P.J. Neglected tropical disease control in the "post-American world" PLoS Negl Trop Dis 2010, 4:e812.